COMP <GO>
CUVL vs CAT // EV/EBITDA & P/E VALUATION
Clinuvel Pharmaceuticals Limited (NASDAQ) VS. Caterpillar Inc. (NYSE) • 15-METRIC TALLY: CUVL 7
— CAT 4
▲ EV/EBITDA & P/E VALUATION LEADER: CUVL
LAST: $5.15 (+1.58%) • MKT CAP: $257.8M
valuation
9.7x
LAST: $647.39 (-9.25%) • MKT CAP: $297.59B
valuation
20.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUVL VS. CAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CUVL | CAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.20% | 82.20% | -1.00 | CAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 21.15% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 9.7x | 20.9x | -11.16 | CUVL | /valuation <GO> |
| Free Cash Flow Yield | 10.51% | 3.74% | +6.77 | CUVL | /fcf-yield <GO> |
| Operating Margin | 43.40% | 17.52% | +25.88 | CUVL | /operating-margins <GO> |
| Net Profit Margin | 37.80% | 14.51% | +23.29 | CUVL | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | 18.36% | -12.86 | CAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 1.05% | -0.39 | CAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.34 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | CUVL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 8.46% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.7 | 33.5 | +4.17 | CUVL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.02 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.3x | 26.0x | -15.66 | CUVL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $257.8M | $297.59B | -$297.33B | CAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CUVL REV | CAT REV | CUVL GROSS % | CAT GROSS % | CUVL FCF | CAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.1M | $67.59B | 81.2% | 99.9% | $27.1M | $8.92B |
| FY 2024 | $57.9M | $64.81B | 81.5% | 100.0% | $20.1M | $10.05B |
| FY 2023 | — | $67.06B | — | 99.8% | — | $11.29B |
| FY 2022 | — | $59.43B | — | 99.3% | — | $6.47B |
| FY 2021 | — | $50.97B | — | 30.3% | — | $6.11B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUVL // BETA —
CAT // BETA 1.02